To optimize the anti-tumor activity of anti-PD-1/PD-L1 therapies, we developed an anti-TGF-β/PD-L1 bispecific antibody YM101, which could simultaneously block the PD-1/PD-L1 and TGF-β pathways. Here, TGFB1 is linked to neoplasm.